CFH and hemolytic-uremic syndrome: Anti-CFH Ab-associated HUS has serious clinical manifestations, with a mortality rate of up to 25%, and 20–29% of survivors progress to kidney failure; the recurrence rate of anti-CFH Ab-associated HUS is approximately 20–25% [3].